Skip to main content
SpringerLink
Log in

Chemotherapeutic Drugs and Gallbladder Cancer: Market Potential in India

  • Chapter
  • First Online:
Bioeconomy for Sustainable Development

  • 934 Accesses

Abstract

Gallbladder cancer (GBC) is the most fatal cancer of the biliary tract with poor prognosis. Silent in its infancy, this malignancy remains asymptomatic until aggressive disease has progressed to an advanced and non-curative stage. The overall mean survival rate for patients with GBC is less than 6 months, with a 5-year survival rate of approximately 5% with a high relapse rate. Treatment depends upon the stage of disease, patient’s age, nutritional status, performance status, and cardiopulmonary, hepatic, and renal functions. Complete surgical resection is considered the most curative modality for GBC. Chemotherapy has recently shown its effect on gallbladder cancer. Therapeutic agents, targeting cellular and molecular pathways, can effectively impede tumor growth. Newer drugs are being developed that work which target specific parts of cancer cells or their surrounding environments like tumor blood vessels. This chapter discusses market of chemotherapeutic drugs in India and market drives and government initiatives for the promotion of pharmaceutical sector in India with special emphasis on GBC.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 149.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 199.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 199.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Aaronson S (1991) Growth factors and Cancer. Science 254(5035):1146–1153

    Article  CAS  Google Scholar 

  • American Cancer Society (2014) Cancer facts & figures 2014. American Cancer Society, Atlanta

    Google Scholar 

  • American Cancer Society (2017) Cancer facts & figures 2017. American Cancer Society, Atlanta

    Google Scholar 

  • Anticancer Drugs Market (Drug Type – Cytotoxic Drugs (Alkylating Agents, and Antimetabolites), Targeted Drugs (Monoclonal Antibodies and Tyrosine Kinase Inhibitors), and Hormonal Drugs; Therapy Type – Chemotherapy, Targeted Therapy, and Immunotherapy; Cancer Type – Lung Cancer, Breast Cancer, Leukemia, and Colorectal Cancer) – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017–2025 (2018)

    Google Scholar 

  • Chaturvedi K, Chataway J, Wield D (2007) Policy, markets and knowledge: strategic synergies in Indian pharmaceutical firms. Tech Anal Strat Manag 19(5):565–588

    Article  Google Scholar 

  • Czito BG, Hurwitz HI, Clough RW, Tyler DS, Morse MA, Clary BM, Pappas TN, Fernando NH, Willett CG (2005) Adjuvant external-beam radiotherapy with concurrent chemotherapy after resection of primary gallbladder carcinoma: a 23-year experience. Int J Radiat Oncol Biol Phys 62(4):1030–1034

    Article  Google Scholar 

  • DeStoll M (1788) Rationismendendi, in nosocomiopracticovendobonensi. part 1 lugdunibatavarum, Haak et Socios et A et J Honkoop

    Google Scholar 

  • Dixit R, Pandey M, Tripathi SK, Dwivedi AND, Shukla VK (2017) Comparative analysis of mutational profile of sonic hedgehog gene in gallbladder cancer. Dig Dis Sci 62(3):708–714

    Article  CAS  Google Scholar 

  • Dixit R, Shukla VK, Pandey M (2012) Molecular alterations in gallbladder cancer. World J Pathol 1:7

    Google Scholar 

  • Dixit R, Shukla VK (2014) Why is gallbladder cancer common in the Gangetic Belt? In: Perspectives in cancer prevention-translational cancer research. Springer, New Delhi, pp 145–151

    Chapter  Google Scholar 

  • Dixit R, Singh G, Pandey M, Basu S, Bhartiya SK, Singh KK, Shukla VK (2016) Association of methylenetetrahydrafolate reductase gene polymorphism (MTHFR) in patients with gallbladder cancer. J Gastrointest Cancer 47(1):55–60

    Article  CAS  Google Scholar 

  • Dixit R (2015) Gene profiling of gallbladder cancer. Ph.D. thesis, Banaras Hindu University, Varanasi, India

    Google Scholar 

  • Dutta U (2012) Gallbladder cancer. Can newer insights improve the outcome? J Gastroenterol Hepatol 27(4):642–653

    Article  Google Scholar 

  • Dwivedi AND, Jain S, Dixit R (2015) Gall bladder carcinoma: aggressive malignancy with protean loco-regional and distant spread. World J Clin Cases 3(3):231–244

    Article  Google Scholar 

  • Frost & Sullivan (2017) Preference to targeted therapies and patient centric approaches drive transformations in oncology drug delivery market

    Google Scholar 

  • Greene W (2007) The emergence of India’s pharmaceutical industry and implications for the U.S. Generic Drug Market. U.S. International Trade Commission

    Google Scholar 

  • Houry S, Barrier A, Huguier M (2001) Irradiation therapy for gallbladder carcinoma: recent advances. J Hepato-Biliary-Pancreat Surg 8(6):518–524

    Article  CAS  Google Scholar 

  • Hundal R, Shaffer EA (2014) Gallbladder cancer: epidemiology and outcome. Clin Epidemiol 6:99–109

    Google Scholar 

  • Indian Pharmaceuticals Industry Report (2019) India brand equity foundation

    Google Scholar 

  • Kresl JJ, Schild SE, Henning GT, Gunderson LL, Donohue J, Pitot H, Haddock MG, Nagorney D (2002) Adjuvant external beam radiation therapy with concurrent chemotherapy in the management of gallbladder carcinoma. Int J Radiat Oncol Biol Phys 52(1):167–175

    Article  Google Scholar 

  • Kumar A, Kumar M, Dixit R, Jaiswal R, Srivastava V, Pandey M (2012) Presence of human papilloma virus and EGFR expression does not predict response to neoadjuvant chemotherapy in oral cancer. World J Surg Med Radiat Oncol 1:103–110

    Google Scholar 

  • McKinsey & Company report (2009) India Pharma 2020: propelling access and acceptance, realising true potential

    Google Scholar 

  • Mhatre SS, Nagrani RT, Budukh A, Chiplunkar S, Badwe R, Patil P, Laversanne M, Rajaraman P, Bray F, Dikshit R (2016) Place of birth and risk of gallbladder cancer in India. Indian J Cancer 53:304–308

    Article  CAS  Google Scholar 

  • Misra A, Misra S, Chaturvedi A, Srivastava PK (2002) Case report. Orbital metastasis from gall bladder carcinoma. Br J Radiol 75(889):72–73

    Article  CAS  Google Scholar 

  • Misra S, Chaturvedi A, Misra NC, Sharma ID (2003) Carcinoma of the gallbladder. Lancet Oncol 4:167–176

    Article  Google Scholar 

  • National Cancer Registry Programme (2013) Three years report of population based cancer registries; 2009–2011. Indian Council of Medical Research, New Delhi

    Google Scholar 

  • National Pharmaceutical Policy (2006) Department of Chemicals 2 and Petrochemicals, Government of India, Dec. 28, 2005

    Google Scholar 

  • Pandey M, Kannepali KK, Dixit R, Kumar M (2018) Effect of neoadjuvant chemotherapy and its correlation with HPV status, EGFR, Her-2-neu, and GADD45 expression in oral squamous cell carcinoma. World J Surg Oncol 16:20

    Article  Google Scholar 

  • Pandey P, Pandey M, Singh KK, Dixit R, Shukla VK (2017) Health related quality of life in patients of the gallbladder cancer with treatment. Int J Biol Med Res 8(2):5948–5953

    Google Scholar 

  • Pignochino Y, Sarotto I, Peraldo-Neia C, Penachioni JY, Cavalloni G, Migliardi G, Casorzo L, Chiorino G, Risio M, Bardelli A, Aglietta M, Leone F (2010) Targeting EGFR/HER2 pathways enhances the antiproliferative effect of gemcitabine in biliary tract and gallbladder carcinomas. BMC Cancer 10:631

    Article  CAS  Google Scholar 

  • Qin TJ, Zhao XH, Yun J, Zhang LX, Ruan ZP, Pan BR (2008) Efficacy and safety of gemcitabine-oxaliplatin combined with huachansu in patients with advanced gallbladder carcinoma. World J Gastroenterol 14(33):5210–5216

    Article  CAS  Google Scholar 

  • Rakić M, Patrlj L, Kopljar M, Kliček R, Kolovrat M, Loncar B, Busic Z (2014) Gallbladder cancer. Hepatobiliary Surg Nutr 3(5):221–226

    Google Scholar 

  • Shukla VK, Das PC, Dixit R, Bhartiya SK, Basu S, Raman MJ (2012) Study of AP endonuclease (APEX1/REF1), a DNA repair enzyme, in gallbladder carcinoma. Anticancer Res 32(4):1489–1492

    CAS  Google Scholar 

  • Shukla VK, Khandelwal C, Roy SK, Vaidya MP (1985) Primary carcinoma of the gall bladder: a review of a 16-year period at the University Hospital. J Surg Oncol 28(1):32–35

    Article  CAS  Google Scholar 

  • Todoroki T (2000) Chemotherapy for gallbladder carcinoma – a surgeon’s perspective. Hepato-Gastroenterology 47:948–955

    CAS  Google Scholar 

  • Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, Madhusudan S, Iveson T, Hughes S, Pereira SP, Roughton M, Bridgewater J, ABC-02 Trial Investigators (2010) Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 362(14):1273–1281

    Article  CAS  Google Scholar 

  • Xiu AX, Hong TS, Hezel AF, Kooby DA (2010) Current management of gallbladder carcinoma. Oncologist 15:168–181

    Article  Google Scholar 

  • Zhao DY, Lim KH (2017) Current biologics for treatment of biliary tract cancers. J Gastrointest Oncol 8(3):430–440

    Article  Google Scholar 

Download references

Acknowledgment

RD is grateful to the Department of Health Research, New Delhi, for providing financial support through the Women Scientists Scheme.

Author information

Authors and Affiliations

  1. Department of General Surgery, Institute of Medical Sciences, Banaras Hindu University, Varanasi, Uttar Pradesh, India

    Ruhi Dixit, Punam Pandey & V. K. Shukla

  2. Department of Surgical Oncology, Institute of Medical Sciences, Banaras Hindu University, Varanasi, Uttar Pradesh, India

    Manoj Pandey

Authors
  1. Ruhi Dixit
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Manoj Pandey
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Punam Pandey
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. V. K. Shukla
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Biochemistry, Institute of Science, Banaras Hindu University, Varanasi, Uttar Pradesh, India

    Chetan Keswani

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Singapore Pte Ltd.

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Dixit, R., Pandey, M., Pandey, P., Shukla, V.K. (2020). Chemotherapeutic Drugs and Gallbladder Cancer: Market Potential in India. In: Keswani, C. (eds) Bioeconomy for Sustainable Development. Springer, Singapore. https://doi.org/10.1007/978-981-13-9431-7_20

Download citation

Publish with us

Policies and ethics

Search

Navigation